On The Fly
| ShowHide Related Items >><< - 11/07/22
- Synaptics senior VP McFarland sells 12,299 common shares
- 10/28/22
- Synaptics acquires Emza Visual Sense, extends leadership position
- 01/17/23
- Privia Health announces launches of ACOs in Delaware and North Carolina
- 12/05/22
- NeoGenomics names Jeffrey Sherman as new CFO
- 11/15/22
- Privia Health announces Butler resigned from board of directors
- 10/03/22
- Director of Privia Health sold 80,853 shares of company stock
- $107.96 /
-2.045 (-1.86%) - 01/09/23
- Xenon Pharmaceuticals outlines key milestone opportunities for 2023
- 01/09/23
- Voyager, Neurocrine enter collaboration to advance multiple gene therapies
- 12/22/22
- Neurocrine: FDA accepts sNDA for valbenazine
- 12/06/22
- Neurocrine announces NBI-827104 did not meet its primary endpoint in Phase 2
- $188.78 /
+35.675 (+23.30%) - 02/01/23
- Meta cuts FY23 total expenses view to $89B-$95B from $94B-$100B
- 02/01/23
- Meta says 2023 will be 'a year of efficiency'
- 02/01/23
- Meta Platforms announces $40B increase in share repurchase authorization
- 02/01/23
- Meta Platforms reports FoA and RL segment restructuring charges
- 01/17/23
- Lightspeed announces reorganization, 10% workforce reduction
- 12/30/22
- Lightspeed announces Saintil to step down from board of directors
- 12/29/22
- Lightspeed rises 7.8%
- 12/06/22
- Lightspeed names Kady Srinivasan as Chief Marketing Officer
- 02/02/23
- Nordstrom ends afterhours session up 31% after WSJ report on Ryan Cohen stake
- 01/25/23
- Nordstrom Default Rating downgraded to junk by Fitch
- 01/19/23
- Nordstrom falls 7% to $16.27 after cutting FY22 outlook
- 01/19/23
- Nordstrom cuts FY22 EBIT margin view to 2.8%-3.1% from 4.1%-4.4%
- 01/24/23
- International Paper to sell ownership in Ilim joint venture for $484M
- 12/06/22
- Herbalife Nutrition falls -19.5%
- 12/06/22
- Herbalife Nutrition falls -16.6%
- 12/06/22
- Herbalife Nutrition falls -15.0%
- 12/05/22
- Herbalife Nutrition falls 10% to $15.70 after offering $250M in convertible debt
- 09/26/22
- H.B. Fuller names Celeste Mastin as new CEO
- 09/21/22
- H.B. Fuller narrows FY22 adjusted EBITDA view to $540M-$550M from $530M-$550M
- 02/02/23
- Ford sees FY23 capital expenditures $8B-$9B
- 02/02/23
- Ford down 6% after Q4 earnings report
- 02/02/23
- Ford declares regular Q1 dividend of 15c, supplemental dividend of 65c
- 02/02/23
- Ford reports January U.S. sales up 2% to 146,356 vehicles
- 02/02/23
- Enphase Energy demonstrates bidirectional EV charger technology
- 01/30/23
- Enphase Energy expands solar deployments in Brazil
- 01/26/23
- Enphase, Enerix to expand solar, battery storage product offerings in Europe
- 01/17/23
- Enphase Energy expands IQ8 microinveter deployments in the Netherlands
DAWN Day One Biopharmaceuticals - 01/08/23
- Day One announces top line data from pivotal Phase 2 FIREFLY-1 trial
- 10/17/22
- Day One Biopharmaceuticals announces CRADA with NCI for tovorafenib
- 09/12/22
- Day One Biopharmaceuticals appoints Nicholson as chairman
- 12/19/22
- Cardinal Health announces Aaron Alt as chief financial officer
- 12/12/22
- Yellow Corp appoints Annlea Rumfola as CIO
- 11/14/22
- Elliott made Triple Flag Precious Metals top holding during Q3
- 09/15/22
- PayrHealth announces collaboration with Cardinal Health
- $209.24 /
-5.265 (-2.45%) - 02/01/23
- Boeing awarded $1.62B Air Force contract
- 02/01/23
- Atlas Air takes delivery of final 747 to be produced by Boeing
- 01/31/23
- Atlas Air takes delivery of Boeing's final 747 production aircraft
- 01/30/23
- Boeing awarded U.S. Air Force contract for 15 KC-46A tankers
AGIO Agios Pharmaceuticals - 12/11/22
- Agios Pharmaceuticals presents updated PYRUKYND long-term extension data
- 12/11/22
- Agios Pharmaceuticals presents updated PYRUKYND data
- 12/06/22
- Agios Pharmaceuticals appoints Tsveta Milanova as CCO
- 11/03/22
- Agios Pharmaceuticals expects cash to fund operations through catalysts
- 02/03/23 UBS
- International Paper upgraded to Neutral from Sell at UBS
- 02/03/23 UBS
- International Paper upgraded to Neutral from Sell at UBS
- 02/02/23 Argus
- International Paper price target raised to $50 from $43 at Argus
- 02/01/23 Truist
- International Paper price target raised to $38 from $30 at Truist
- $209.24 /
-5.265 (-2.45%) - 02/03/23 RBC Capital
- Boeing downgraded to Sector Perform from Outperform at RBC Capital
- 01/30/23 Jefferies
- Boeing price target raised to $250 from $240 at Jefferies
- 01/26/23 Morgan Stanley
- Boeing remains a 'show me story,' says Morgan Stanley
- 01/12/23 Credit Suisse
- Credit Suisse upgrades Boeing to Neutral, raises price target to $200
- 02/03/23 Credit Suisse
- Lightspeed downgraded to Neutral from Outperform at Credit Suisse
- 02/02/23 CIBC
- Lightspeed downgraded to Neutral from Outperformer at CIBC
- 01/25/23 BofA
- Lightspeed initiated with a Neutral at BofA
- 01/25/23 BofA
- Lightspeed initiated with a Neutral at BofA
- 02/03/23 Craig-Hallum
- Synaptics price target raised to $150 from $120 at Craig-Hallum
- 02/03/23 Susquehanna
- Synaptics price target raised to $145 from $115
- 02/03/23 Oppenheimer
- Synaptics downgraded to Perform from Outperform at Oppenheimer
- 02/03/23 Cowen
- Synaptics price target raised to $150 from $100 at Cowen
- 02/03/23 William Blair
- Nordstrom performance 'begs for an activist role,' says William Blair
- 02/03/23 Gordon Haskett
- Nordstrom upgraded to Hold from Reduce at Gordon Haskett
- 01/30/23 Goldman Sachs
- Nordstrom initiated with a Neutral at Goldman Sachs
- 01/20/23 Deutsche Bank
- Nordstrom price target lowered to $17 from $21 at Deutsche Bank
- 02/03/23 Baird
- Baird upgrades Cardinal Health, sees 'value trap label' ending
- 02/03/23 Baird
- Cardinal Health upgraded to Outperform from Neutral at Baird
- 01/31/23 UBS
- Cardinal Health price target raised to $91 from $78 at UBS
- 11/22/22 Credit Suisse
- Cardinal Health price target raised to $79 from $64 at Credit Suisse
- $188.78 /
+35.675 (+23.30%) - 02/03/23 DA Davidson
- Amazon.com price target raised to $134 from $114 at DA Davidson
- 02/03/23 HSBC
- Meta Platforms downgraded to Reduce from Hold at HSBC
- 02/03/23 DZ Bank
- Meta Platforms upgraded to Hold from Sell at DZ Bank
- 02/02/23 Deutsche Bank
- Meta Platforms price target raised to $200 from $125 at Deutsche Bank
- 02/03/23 Benchmark
- Ford price target lowered to $19 from $21 at Benchmark
- 02/03/23 Deutsche Bank
- Deutsche downgrades Ford to Sell on 'meaningful' earnings risk
- 02/03/23 Deutsche Bank
- Ford downgraded to Sell from Hold at Deutsche Bank
- 01/25/23 JPMorgan
- Ford price target lowered to $15 from $16 at JPMorgan
DAWN Day One Biopharmaceuticals - 02/02/23 Oppenheimer
- Day One Biopharmaceuticals initiated with a Perform at Oppenheimer
- 01/09/23 H.C. Wainwright
- Day One Biopharmaceuticals price target raised to $45 from $35 at H.C. Wainwright
- 01/08/23 Piper Sandler
- Day One Biopharmaceuticals price target raised to $45 from $40 at Piper Sandler
- 12/15/22 H.C. Wainwright
- Day One Biopharmaceuticals initiated with a Buy at H.C. Wainwright
- 02/03/23 BofA
- Herbalife Nutrition initiated with an Underperform at BofA
- 11/01/22 B. Riley
- Herbalife Nutrition price target lowered to $31 from $38 at B. Riley
- 11/01/22 Citi
- Herbalife Nutrition price target lowered to $26 from $30 at Citi
- 10/05/22 Citi
- Herbalife Nutrition price target lowered to $30 from $36 at Citi
AGIO Agios Pharmaceuticals - 02/03/23 Piper Sandler
- Agios Pharmaceuticals initiated with an Overweight at Piper Sandler
- 11/17/22 Goldman Sachs
- Agios Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
- 07/27/22 SVB Securities
- Agios Pharmaceuticals upgraded to Outperform from Market Perform at SVB Securities
- 02/25/22 RBC Capital
- Agios Pharmaceuticals price target raised to $67 from $61 at RBC Capital
- $107.96 /
-2.045 (-1.86%) - 02/03/23 Morgan Stanley
- Neurocrine upgraded to Overweight from Equal Weight at Morgan Stanley
- 12/13/22 RBC Capital
- Neurocrine CAH data appears pushed back, says RBC Capital
- 11/14/22 Evercore ISI
- Neurocrine downgraded to In Line from Outperform at Evercore ISI
- 11/02/22 BMO Capital
- Neurocrine price target raised to $101 from $78 at BMO Capital
- 02/03/23 Citi
- H.B. Fuller upgraded to Buy from Neutral at Citi
- 01/23/23 Citi
- H.B. Fuller price target raised to $72 from $65 at Citi
- 01/20/23 Deutsche Bank
- H.B. Fuller price target raised to $78 from $72 at Deutsche Bank
- 01/20/23 Baird
- H.B. Fuller price target lowered to $80 from $85 at Baird
- 02/03/23 Truist
- Enphase Energy price target lowered to $285 from $325 at Truist
- 02/03/23 Janney Montgomery Scott
- Enphase Energy initiated with a Neutral at Janney Montgomery Scott
- 02/01/23 Barclays
- SolarEdge price target lowered to $392 from $396 at Barclays
- 02/01/23 Barclays
- Enphase Energy price target lowered to $251 from $311 at Barclays
- 02/03/23 Goldman Sachs
- Privia Health initiated with a Buy at Goldman Sachs
- 01/17/23 Piper Sandler
- Piper Sandler would be a buyer of Privia Health following CMS data
- 01/09/23 BTIG
- Privia Health price target lowered to $40 from $45 at BTIG
- 12/08/22 Stifel
- Privia Health initiated with a Buy at Stifel
- 02/02/23
- Synaptics sees Q3 revenue $310M-$340M, consensus $365.38M
- 02/02/23
- Synaptics reports Q2 EPS $2.20, consensus $2.34
- 11/03/22
- Synaptics sees Q2 revenue $350M-$380M, consensus $448.22M
- 11/03/22
- Synaptics reports Q1 EPS $3.52, consensus $3.31
- 11/10/22
- Privia Health raises FY22 revenue view to $1.3B-$1.335B from $1.225B-$1.3B
- 11/10/22
- Privia Health reports Q3 adjusted EPS 13c, consensus 0c
- 08/11/22
- Privia Health sees 2022 revenue at high end of $1.225B-$1.3B
- 08/11/22
- Privia Health reports Q2 adjusted EPS 13c vs. 9c last year.
- $107.96 /
-2.045 (-1.86%) - 11/01/22
- Neurocrine reports Q3 non-GAAP EPS $1.08, consensus 79c
- 08/04/22
- Neurocrine reports Q2 non-GAAP EPS 84c, consensus 15c
- $188.78 /
+35.675 (+23.30%) - 02/01/23
- Meta Platforms sees Q1 revenue $26B-$28.5B, consensus $27.14B
- 02/01/23
- Meta Platforms reports Q4 EPS $1.76, consensus $2.22
- 02/01/23
- Notable companies reporting after market close
- 11/09/22
- Meta Platforms backs Q4 revenue outlook $30B-$32.5B, consensus $31.52B
- 02/02/23
- Lightspeed sees FY23 revenue at low end of $730M-$740M, consensus $733.15M
- 02/02/23
- Lightspeed reports Q3 adjusted EPS 0c, consensus (5c)
- 11/03/22
- Lightspeed sees Q3 revenue at constant currency $189M-$194M, consensus $200.48M
- 11/03/22
- Lightspeed reports Q3 adjusted EPS (5c), consensus (7c)
- 01/19/23
- Nordstrom cuts FY22 adjusted EPS view to $1.50-$1.70 from $2.30-$2.60
- 11/22/22
- Nordstrom backs FY22 adjusted EPS view $2.30-$2.60, consensus $2.34
- 11/22/22
- Nordstrom reports Q3 adjusted EPS 20c, consensus 14c
- 11/22/22
- Notable companies reporting after market close
- 01/31/23
- International Paper reports Q4 adjusted EPS 87c, consensus 69c
- 10/27/22
- International Paper reports Q3 adjusted EPS $1.01, consensus $1.21
- 10/31/22
- Herbalife Nutrition reports Q3 EPS 91c, consensus 74c
- 01/18/23
- H.B. Fuller sees FY23 adjusted EPS $4.15-$4.55, consensus $4.63
- 01/18/23
- H.B. Fuller reports Q4 adjusted EPS $1.04, consensus $1.24
- 09/21/22
- H.B. Fuller sees Q4EPS $1.15-$1.30, consensus $1.28
- 09/21/22
- H.B. Fuller reports Q3 EPS $1.06, consensus $1.04
- 02/02/23
- Ford sees FY23 adjusted EBIT of $9B-$11B
- 02/02/23
- Ford reports Q4 adjusted EPS 51c, consensus 62c
- 02/02/23
- Notable companies reporting after market close
- 10/26/22
- Ford reports Q3 adjusted EPS 39c, consensus 27c
- 10/25/22
- Enphase Energy sees Q4 revenue $680M-$720M, consensus $660.21M
- 10/25/22
- Enphase Energy reports Q3 EPS $1.25, consensus $1.08
- 10/25/22
- Notable companies reporting after market close
DAWN Day One Biopharmaceuticals - 11/07/22
- Day One Biopharmaceuticals reports Q3 EPS (53c), consensus (53c)
- 08/04/22
- Day One Biopharmaceuticals reports Q2 EPS (60c), consensus (49c)
- 02/02/23
- Cardinal Health raises FY23 EPS view to $5.20-$5.50 from $5.05-$5.40
- 02/02/23
- Cardinal Health reports Q2 EPS $1.32, consensus $1.14
- 02/01/23
- Notable companies reporting before tomorrow's open
- $209.24 /
-5.265 (-2.45%) - 01/25/23
- Boeing reports Q4 core EPS ($1.75), consensus 26c
- 01/24/23
- Notable companies reporting before tomorrow's open
- 10/26/22
- Boeing reports Q3 core EPS ($6.18), consensus 2c
AGIO Agios Pharmaceuticals - 11/03/22
- Agios Pharmaceuticals reports Q3 EPS ($1.49), consensus ($1.76)
- 08/04/22
- Agios Pharmaceuticals reports Q2 EPS ($1.68), consensus ($1.75)
|